Table 3.

Correlation Between the 28 Biomarkers Predictive of the Composite Outcome According to the OPLS Analysis and Echocardiographic Markers of Diastolic Dysfunction and Structural Heart Disease

Biomarker Short NameE/e′LAVILVMI
rP ValuerP ValuerP Value
Positive predictors
 GDF-150.321*0.009*0.1830.1190.01450.361
 CHI3L10.0910.469−0.0080.9430.2700.088
 CCL200.292*0.018*0.316*0.006*0.0340.833
 PRL0.1970.1150.317*0.006*0.0640.689
 SPON10.473*<0.001*0.0750.5270.0770.632
 AGRP0.268*0.031*0.0130.9140.1460.364
 AM0.389*0.001*0.0880.456−0.0840.603
 FABP40.352*0.004*0.397*0.001*0.0720.655
 FGF-230.2760.026*0.2190.0610.1300.416
 TNF-R10.427*<0.001*0.0380.7460.1910.231
 IL-80.250*0.044*0.0080.944−0.1210.451
 IL-60.265*0.033*0.1920.1010.1040.517
 CD400.343*0.005*−0.0330.7780.0390.808
 TRAIL-R20.424*<0.001*0.0140.9070.0560.730
 Gal-30.393*0.001*0.0260.9150.0220.892
 U-PAR0.442*<0.001*0.0230.8470.0360.823
 ST20.296*0.017*0.271*0.020*0.1190.459
 PAR-10.342*0.005*−0.0800.5010.0760.638
 NT-proBNP (ELISA)0.1510.2330.307*0.008*−0.0880.583
 MMP-120.461*<0.001*−0.0300.798−0.0770.634
 VEGF-A0.411*<0.001*0.0780.5110.1530.340
 MMP-70.392*0.001*0.0330.7830.0960.549
 TF0.351*0.004*0.0440.709−0.1350.400
 CSTB0.313*0.011*−0.0240.842−0.0410.797
 RETN0.265*0.033*−0.1730.1400.1920.230
Negative predictors
 KLK60.301*0.015*0.0460.695−0.2110.186
 TRANCE0.0030.984−0.0410.7240.2390.133
 GAL0.0020.988−0.0640.587−0.1020.525
 TRAIL0.1010.424−0.0030.828−0.0340.831
  • AGRP indicates agouti-related protein; AM, adrenomedullin; CCL20, C–C motif chemokine 20; CHI3L1, chitinase-3–like protein 1; CSTB, cystatin-B; FABP4, fatty acid–binding protein; FGF, fibroblast growth factor; Gal-3, galectin-3; GDF, growth/differentiation factor; IL, interleukin; KLK6, kallikrein-6; LAVI, left atrial volume index; LVMI, Left ventricular mass index; MMP, matrix metalloproteinase; NT-proBNP, N-terminal probrain natriuretic peptide; OPLS, orthogonal partial least square; PAR, proteinase-activated receptor; PRL, prolactin; RETN, resistin; SPON1, spondin-1; TF, tissue factor; TNF, tumor necrosis factor receptor; TRAIL, TNF-related apoptosis-inducing ligand; TRANCE, TNF-related activation-induced cytokine; U-PAR, urokinase plasminogen activator surface receptor; and VEGF-A, vascular endothelial growth factor A.